Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 8Salivary Gland Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pathologic Complete Response 1Hemangiosarcoma 1Heart Failure 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy 1Endometrial Neoplasms 1Colorectal Neoplasms 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 11Oxaliplatin 6Fluorouracil 6Capecitabine 5pembrolizumab 4Paclitaxel 4Leucovorin 4durvalumab 3Radiotherapy 3Folfox protocol 3Drug Therapy 3dehydroftorafur 2Trastuzumab 2Specimen Handling 2Radiation 2Metformin 2Magnetic Resonance Spectroscopy 2Itraconazole 2Irinotecan 2Docetaxel 2Cisplatin 2Carboplatin 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma Of Esophagus × Ado-Trastuzumab Emtansine × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡